For licensed medical professionals and compounding pharmacies only. Not for sale to the general public.  ·  787-822-8197
Build Your Order Apply for Wholesale
Build Your Order Products For Clinics For Pharmacies For Brands Quality Wholesale Resources About Contact Apply for Wholesale
Product sourcing reference

GLP-1 & Related Compounds

Separate approved medicines, compounded preparations and investigational compounds before comparing GLP-1-related sourcing options.

7 compounds in this category

Reference variants and pricing

Add variants to your order request. Prices are reference estimates pending eligibility and availability review.

Cagrilintide

GLP-1 from $44.85/unit
  • 10mgVial · confirm physical formCAS 1415456-99-3
    $44.85/vial$35.88/vial at 1,000+ vials of this item
    vials, packs of 10

Cagrilintide / Semaglutide Blend

GLP-1 from $25.88/unit
  • 10mg (5/5)Vial · confirm physical formCAS Multi-component
    $25.88/vialCloseout estimate Regular $51.75. Subject to confirmation; not a stock promise.
    vials, packs of 10

Retatrutide

GLP-1 from $17.69/unit
  • 10mgVial · confirm physical formCAS 2381089-83-2
    $17.69/vial$14.15/vial at 1,000+ vials of this item
    vials, packs of 10
  • 20mgVial · confirm physical formCAS 2381089-83-2
    $24.15/vial$19.32/vial at 1,000+ vials of this item
    vials, packs of 10
  • 30mgVial · confirm physical formCAS 2381089-83-2
    $36.69/vial$29.35/vial at 1,000+ vials of this item
    vials, packs of 10
  • 60mgVial · confirm physical formCAS 2381089-83-2
    $54.63/vial$43.70/vial at 1,000+ vials of this item
    vials, packs of 10

Retatrutide / Cagrilintide Blend

GLP-1 from $14.95/unit
  • 10mg (5/5)Vial · confirm physical formCAS Multi-component
    $14.95/vialCloseout estimate Regular $29.90. Subject to confirmation; not a stock promise.
    vials, packs of 10

Semaglutide

GLP-1 from $14.38/unit
  • 5mgVial · confirm physical formCAS 910463-68-2
    Quote requiredReference listed as discontinued. Historical reference $5.75/vial; not an offer.
    Ask for a quote
  • 10mgVial · confirm physical formCAS 910463-68-2
    $15.53/vial$12.42/vial at 1,000+ vials of this item
    vials, packs of 10
  • 20mgVial · confirm physical formCAS 910463-68-2
    $14.38/vialCloseout estimate Regular $28.75. Subject to confirmation; not a stock promise.
    vials, packs of 10
  • 30mgVial · confirm physical formCAS 910463-68-2
    $14.38/vialCloseout estimate Regular $28.75. Subject to confirmation; not a stock promise.
    vials, packs of 10

Tirzepatide

GLP-1 from $10.10/unit
  • 10mgVial · confirm physical formCAS 2023788-19-2
    $10.10/vial$8.08/vial at 1,000+ vials of this item
    vials, packs of 10
  • 30mgVial · confirm physical formCAS 2023788-19-2
    $27.17/vial$21.74/vial at 1,000+ vials of this item
    vials, packs of 10
  • 60mgVial · confirm physical formCAS 2023788-19-2
    $64.69/vial$51.75/vial at 1,000+ vials of this item
    vials, packs of 10

Triple Antagonist Spray

GLP-1 from $33.75/unit
  • 10mgSpray bottle
    $33.75/bottle$22.50/bottle at 50+ bottles of this item
    bottles

Shortage status is not permanent authorization

Semaglutide and tirzepatide require a current review of FDA shortage and compounding updates. Previous shortage policies are not a standing permission to supply copies of approved medicines.

Investigational compounds belong in a different review

Retatrutide should not be treated as an equivalent purchasing alternative to an approved GLP-1 medicine. Trial activity does not establish marketing approval or a lawful clinic supply offer.

Compound-specific review guides

Semaglutide

Review the exact semaglutide formulation and current compounding restrictions before discussing a purchase. A historical shortage or a supplier listing does not establish an ongoing exemption.

Tirzepatide

A tirzepatide inquiry requires a current regulatory review, not a general promise of 503B office-use supply. Specify the exact product and transaction before requesting terms.

Retatrutide

Retatrutide is discussed in investigational research. This reference page does not offer it for treatment, confirm clinical availability, or imply an authorized compounding pathway.

Choose the appropriate review path

Compare GLP-1-related references by regulatory position

Begin with the distinction between a labeled approved product, a proposed compounded preparation and an investigational substance. Semaglutide salt identity and tirzepatide preparation details need separate checks; neither establishes an automatic substitute for the other.

Make the comparison specific

FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. A blend or spray label does not remove an ingredient restriction. Record exact ingredients, concentration and presentation before comparing any reference estimate.

Regulatory context: FDA: unapproved GLP-1 drugs and ingredient restrictions. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.

Related guidance: Weight-loss clinic sourcing requirements. These references support a review, not a treatment recommendation or supply authorization.

Call Apply for Wholesale